Ixekizumab

Hypersensitivity. Active infection (e.g. TB). Pregnancy. Administration of live vaccine.

Patients with chronic or recurrent infection and inflammatory bowel disease (e.g. Crohn’s disease, ulcerative colitis). Lactation.

Significant: Hypersensitivity reactions (e.g. urticaria, angioedema, anaphylaxis), infections (e.g. upper respiratory tract infection, oral candidiasis, conjunctivitis, tinea infections).
Blood and lymphatic system disorders: Neutropenia, thrombocytopenia.
Gastrointestinal disorders: Nausea.
General disorders and administration site conditions: Inj site reactions (e.g. erythema, pain).
Infections and infestations: Herpes simplex (mucocutaneous), influenza, cellulitis.
Respiratory, thoracic and mediastinal disorders: Oropharyngeal pain, upper respiratory tract infection, rhinitis.
Skin and subcutaneous tissue disorders: Rash, urticaria, eczema.

Monitor for hypersensitivity reactions, signs and symptoms of infection, active TB (during and after treatment) and inflammatory bowel disease.

Potentially Fatal: May enhance the adverse effects and diminish the therapeutic effect of live vaccines.

Description:
Mechanism of Action: Ixekizumab is a humanised immunoglobulin G₄ (IgG₄ kappa) monoclonal antibody that selectively binds with the interleukin 17A (IL-17A), a cytokine involved in normal inflammatory and immune responses, thus inhibiting the release of proinflammatory cytokines and chemokines.
Pharmacokinetics:
Absorption: Bioavailability: 60-81%. Time to peak plasma concentration: Approx 4 days.
Distribution: Crosses placenta. Volume of distribution steady-state: 7.1 L.
Metabolism: Expected to be degraded into small peptides and amino acids via catabolic pathways.
Excretion: Elimination half-life: 13 days.

Store between 2-8°C or below 30°C for up to 5 days. Do not freeze. Protect from light. Any unused portion should be disposed of in accordance with local requirements.

Thuốc trị vẩy nến, tăng tiết bã nhờn & vảy cá

L04AC13 - ixekizumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.

Anon. Ixekizumab. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 07/08/2019.

Anon. Ixekizumab. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 07/08/2019.

Buckingham R (ed). Ixekizumab. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/08/2019.

Joint Formulary Committee. Ixekizumab. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/08/2019.

Taltz Injection Solution (Eli Lilly and Company). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 07/08/2019.